Abstract：
UNASSIGNED: To evaluate the effectiveness, safety, and stability of a modified PRESBYOND Laser Blended Vision protocol (Carl Zeiss Meditec AG) for correcting hyperopic astigmatism and presbyopia, using Custom Refractive Software Master (CRSM) targeting over a 6-month period.
UNASSIGNED: A total of 636 eyes of 318 patients with a mean age of 51.05 ± 4.71 years (range: 40 to 60 years) met the inclusion and exclusion criteria. All patients completed a 6-month follow-up. CRSM software was used to generate ablation profiles for the MEL90 excimer laser (Carl Zeiss Meditec AG). The target refraction was emmetropic for the dominant eyes and between -0.75 and -1.12 diopters (D) for the near eyes.
UNASSIGNED: Visual and refractive results were studied separately by the dominant and non-dominant eyes. The mean attempt to correct for spherical equivalent refraction was +2.17 ± 1.16 D (range: -1.00 to +5.37 D). The mean attempted cylinder was -0.60 ± 0.75 D (range: -4.00 to 0.00 D). All eyes monocularly achieved uncorrected distance visual acuity (UDVA) of 20/25 or better after refractive treatment and 88% achieved 20/20. Binocularly all eyes achieved UDVA of 20/25 or better and 96.54% achieved 20/20. Ninety-eight percent of the patients maintained their corrected distance visual acuity before surgery and UDVA 6 months after surgery.
UNASSIGNED: This hyperopic micro-anisometropia protocol with PRESBYOND Laser Blended Vision was an effective, safe, and well-tolerated refractive treatment. It was an effective procedure with excellent results for UDVA and uncorrected near visual acuity and demonstrates that binocular summation exists. [ J Refract Surg. 2024;40(7):e480-e489.].
UNASSIGNED: A total of 636 eyes of 318 patients with a mean age of 51.05 ± 4.71 years (range: 40 to 60 years) met the inclusion and exclusion criteria. All patients completed a 6-month follow-up. CRSM software was used to generate ablation profiles for the MEL90 excimer laser (Carl Zeiss Meditec AG). The target refraction was emmetropic for the dominant eyes and between -0.75 and -1.12 diopters (D) for the near eyes.
UNASSIGNED: Visual and refractive results were studied separately by the dominant and non-dominant eyes. The mean attempt to correct for spherical equivalent refraction was +2.17 ± 1.16 D (range: -1.00 to +5.37 D). The mean attempted cylinder was -0.60 ± 0.75 D (range: -4.00 to 0.00 D). All eyes monocularly achieved uncorrected distance visual acuity (UDVA) of 20/25 or better after refractive treatment and 88% achieved 20/20. Binocularly all eyes achieved UDVA of 20/25 or better and 96.54% achieved 20/20. Ninety-eight percent of the patients maintained their corrected distance visual acuity before surgery and UDVA 6 months after surgery.
UNASSIGNED: This hyperopic micro-anisometropia protocol with PRESBYOND Laser Blended Vision was an effective, safe, and well-tolerated refractive treatment. It was an effective procedure with excellent results for UDVA and uncorrected near visual acuity and demonstrates that binocular summation exists. [ J Refract Surg. 2024;40(7):e480-e489.].
摘要：
■为了评估有效性，安全,改进的PRESBYOND激光混合视觉协议（CarlZeissMeditecAG）的稳定性，用于矫正远视散光和老花眼，在6个月内使用自定义折射软件主机(CRSM)定位。
■318名患者的636只眼，平均年龄为51.05±4.71岁（范围：40至60岁）符合纳入和排除标准。所有患者均完成6个月的随访。使用CRSM软件生成MEL90准分子激光器(CarlZeissMeditecAG)的消融曲线。优势眼的目标屈光度为-0.75和-1.12屈光度（D）之间的近眼。
■视觉和屈光结果分别由优势和非优势眼研究。校正球面等效折射的平均尝试为2.17±1.16D（范围：-1.00至5.37D）。尝试的平均圆柱体为-0.60±0.75D（范围：-4.00至0.00D）。屈光治疗后，所有单眼的未矫正远距视力（UDVA）达到20/25或更好，而88％达到20/20。双眼所有眼睛的UDVA达到20/25或更好，96.54％达到20/20。98%的患者在手术前保持矫正视力，在手术后6个月保持UDVA。
■这种具有PRESBYOND激光混合视觉的远视微屈光参差方案是一种有效的，安全,和耐受性良好的屈光治疗。这是一种有效的程序，对UDVA和未矫正的近视敏度具有出色的效果，并证明存在双眼求和。[JRefractSurg.2024；40（7）：e480-e489。].
■318名患者的636只眼，平均年龄为51.05±4.71岁（范围：40至60岁）符合纳入和排除标准。所有患者均完成6个月的随访。使用CRSM软件生成MEL90准分子激光器(CarlZeissMeditecAG)的消融曲线。优势眼的目标屈光度为-0.75和-1.12屈光度（D）之间的近眼。
■视觉和屈光结果分别由优势和非优势眼研究。校正球面等效折射的平均尝试为2.17±1.16D（范围：-1.00至5.37D）。尝试的平均圆柱体为-0.60±0.75D（范围：-4.00至0.00D）。屈光治疗后，所有单眼的未矫正远距视力（UDVA）达到20/25或更好，而88％达到20/20。双眼所有眼睛的UDVA达到20/25或更好，96.54％达到20/20。98%的患者在手术前保持矫正视力，在手术后6个月保持UDVA。
■这种具有PRESBYOND激光混合视觉的远视微屈光参差方案是一种有效的，安全,和耐受性良好的屈光治疗。这是一种有效的程序，对UDVA和未矫正的近视敏度具有出色的效果，并证明存在双眼求和。[JRefractSurg.2024；40（7）：e480-e489。].
